Compugen Ltd. files foreign-issuer reports that document its clinical-stage cancer immunotherapy business, financial results and material corporate developments. Its Form 6-K filings cover quarterly and annual results, interim consolidated financial statements, management discussion and analysis, Inline XBRL financial data, and corporate updates related to programs such as COM701, COM902, rilvegostomig and GS-0321.
The filing record also documents licensing and royalty arrangements, including amendments to the AstraZeneca rilvegostomig agreement, as well as proxy materials, annual general meeting voting results, board composition and registration-statement incorporation matters under Form F-3. These disclosures frame Compugen's capital resources, collaboration economics, governance actions, clinical-development disclosures and foreign private issuer reporting obligations.
Compugen Ltd’s President and CEO, Ophir Eran, filed an initial statement of ownership showing both ordinary shares and stock options in the company. He directly holds 11,375 ordinary shares, including 7,821 restricted stock units that begin vesting in 11 equal quarterly installments starting on March 31, 2026, subject to continued service. He also holds multiple share options over Compugen ordinary shares with exercise prices ranging from $0.8292 to $14.4000, expiring between 2026 and 2035, many of which vest or continue vesting in quarterly installments tied to ongoing service.
Compugen Ltd Chief Medical Officer Michelle Mahler filed an initial ownership report showing option and share holdings in the company. She holds share options over 40,000, 35,750 and 18,000 Ordinary Shares with exercise prices of $0.8793, $1.6900 and $1.4600, expiring between 2033 and 2035. She also holds 23,125 Ordinary Shares, including 20,122 restricted stock units that vest gradually in quarterly installments starting on March 31, 2026 and September 30, 2026, conditioned on continued service.
Compugen Ltd filed an initial Form 3 for Zurit Levine, SVP, Business Development, detailing existing equity holdings. Levine directly holds 29,375 Ordinary Shares, including 25,821 restricted stock units that vest in staged quarterly installments. She also holds multiple share options over Ordinary Shares with exercise prices between 0.8292 and 14.4000, expiring from 2026 through 2035. These entries reflect current positions, not new market purchases or sales.
COMPUGEN LTD director Mathias Hukkelhoven filed an initial ownership report showing his existing equity stake in the company. The filing lists direct holdings of 10,000 Ordinary Shares and several stock option awards over Ordinary Shares with different exercise prices and maturities.
He holds options over 35,000 Ordinary Shares at an exercise price of $3.09 expiring in 2032, 10,000 shares at $1.15 expiring in 2033, 8,000 shares at $1.69 expiring in 2034, 12,000 shares at $1.97 expiring in 2034, and 10,000 shares at $1.46 expiring in 2035.
The disclosure also notes 9,216 restricted stock units, with portions vesting in quarterly installments starting on April 1, 2026 and on October 1, 2026, subject to his continued service. The document records holdings only and does not show new purchases or sales.
Compugen Ltd director Michele Holcomb filed an initial ownership report showing equity awards tied to her service. She holds 15,000 Ordinary Shares directly and a share option for 20,000 Ordinary Shares at an exercise price of $1.76 per share, expiring on February 11, 2036. The option vests 25% on April 1, 2027, with the remainder vesting in 12 equal quarterly installments, and related RSUs follow the same vesting schedule, all subject to her continued service to Compugen.
Compugen Ltd director Halevy Gilead has filed an initial ownership report detailing existing equity awards and shareholdings. The filing lists several share options over Ordinary Shares with exercise prices ranging from $1.15 to $14.40 per share and expirations between 2028 and 2035. It also shows direct ownership of 11,407 Ordinary Shares. Footnotes state that this share figure includes 9,216 restricted stock units, with portions scheduled to vest in quarterly installments beginning on April 1, 2026 and on October 1, 2026, subject to continued service.
Compugen Ltd.’s Chief Operating Officer Pierre Ferre has filed a Form 3 reporting his existing holdings of share options. The filing lists options over a total of 400,000 Ordinary Shares, with exercise prices ranging from 3.0000 to 6.4500 and expiration dates between 2031 and 2035.
One option grant is already fully vested, while others vested or vest 25% on dates in 2023, 2024 and 2025, with the remaining portions vesting in 12 equal quarterly installments, subject to his continued service. A further grant begins vesting 25% on September 30, 2026, then continues in 12 quarterly installments.
Compugen Ltd director Anat Cohen-Dayag has filed an initial ownership report showing existing equity holdings in the company. She holds 108,622 Ordinary Shares directly, including 36,091 restricted stock units (RSUs) that vest in 11 equal quarterly installments beginning on March 31, 2026, subject to continued service.
She also holds multiple share options to buy Ordinary Shares, with exercise prices ranging from $1.02 to $14.40 and expiration dates between 2026 and 2035. This filing records current positions and does not report any new purchases or sales of Compugen shares.
COMPUGEN LTD executive Sharon Kredo Russo, SVP Research & Discovery, filed an initial ownership report showing equity-based compensation rather than any recent share purchases or sales. She holds 19,500 Ordinary Shares in the form of restricted stock units that vest 50% on December 31, 2027, with the remainder vesting in eight equal quarterly installments thereafter, subject to continued service. She also holds a share option covering 26,000 Ordinary Shares at an exercise price of $1.64 per share, expiring November 6, 2035, which vests on the same 50%-then-quarterly schedule, also conditioned on continued service to the company.
Compugen Ltd., an Israel-based immuno-oncology company, reports a 2025 net profit of $35.3 million after years of losses, though it still carries an accumulated deficit of about $453.4 million. The turnaround is driven largely by partnership revenue rather than product sales.
Revenue from collaborations reached roughly $72.8 million in 2025, following $27.9 million in 2024 and $33.5 million in 2023, including a $65 million additional upfront payment from AstraZeneca and substantial upfront and milestone payments from Gilead. Management believes existing cash, deposits and marketable securities can fund operations into 2029, but it still expects future losses and may need more capital.
The company’s near-term outlook rests on four clinical-stage programs—COM701, COM902, GS-0321 and AstraZeneca’s rilvegostomig—and on its Unigen AI/ML discovery platform. The report highlights extensive risks around clinical trial outcomes, patient enrollment, dependence on a small number of partners, manufacturing, competition from advanced modalities such as ADCs and T cell engagers, and the unproven nature of its AI-driven target discovery approach.